Published in Medicine and Law Weekly, August 3rd, 2007
Study 1: Research findings, "Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor," are discussed in a new report. "Sunitinib (SU-11248, Sutent) inhibits at least eight receptor protein-tyrosine kinases including vascular endothelial growth factor receptors 1-3 (VEGFR1-VEGFR3), platelet-derived growth factor receptors (PDGFRalpha and PDGFRbeta), stem cell factor receptor (Kit), Flt-3, and colony-stimulating factor-1 receptor (CSF-1R). VEGFR1 and VEGFR2 play key roles in vasculogenesis and angiogenesis," scientists writing in the journal Biochemical and Biophysical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly